Mirati Therapeutics Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Company name
- Mirati Therapeutics Inc.
- Organisation type
- Industry
- Registered legal name
- Mirati Therapeutics, Inc.
- Registry sponsor category
- Industry
- Mirati Therapeutics
- Mirati Therapeutics Inc.
- Legal Entity Identifier (LEI)
- 529900GYRW59IDQV6N54
Related records
Trials (74)
- A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
- A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
- A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
- A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
- A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
- A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
- A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
- A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
- A Study to Explore the Effect of Acid-reducing Agents
- A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
- Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
- Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)